What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn’s Disease Treated With Vedolizumab?

Timothy Card, FRCR, PhD,* Jing Xu, PhD,† Huifang Liang, MD, PhD,‡ and Fatima Bhayat, MBChB, PhD§

Background: Progressive multifocal leukoencephalopathy is a serious condition linked to certain diseases and immunosuppressant therapies, including the $\alpha_4$ integrin antagonist natalizumab. No cases have been reported to date with vedolizumab, a selective antagonist of the $\alpha_4\beta_7$ integrin expressed on gut-homing lymphocytes. This analysis aimed to describe the current and future expected occurrence of progressive multifocal leukoencephalopathy with vedolizumab use, were the risk the same as in other populations in which this disease has been studied.

Methods: The expected number of vedolizumab-associated progressive multifocal leukoencephalopathy cases was estimated up to May 19, 2016, and modeled up to 2034. These estimates were based on the cumulative exposure to the drug, assuming an equivalent risk to that of patients treated with natalizumab or those from other reference populations where progressive multifocal leukoencephalopathy has been examined. Future cases were modeled based on similar risks and projected sales.

Results: The cumulative vedolizumab exposure was estimated at 54,619 patient-years, with a 95% confidence interval of 0.0 to 6.75 cases per 100,000 patient-years. An estimated 30.2 (95% confidence interval, 19.4–40.9) cases of progressive multifocal leukoencephalopathy would have occurred if vedolizumab had the same risk as that of natalizumab. There would be a 50% chance of the first case occurring by 2018, assuming an equivalent risk to the general population.

Conclusions: These analyses indicate that the risk of progressive multifocal leukoencephalopathy with vedolizumab is small, and unlikely to be above 6.75 cases per 100,000 patient-years.

Key Words: epidemiology, clinical trials, progressive multifocal leukoencephalopathy, inflammatory bowel disease, vedolizumab

INTRODUCTION

Progressive multifocal leukoencephalopathy (PML) is a disabling and potentially fatal neurological syndrome caused by the John Cunningham virus (JCV) that can occur in the setting of severe immunosuppression. In addition to infection with human immunodeficiency virus (HIV), the use of immunomodulatory therapies—including the $\alpha_4$ integrin antagonist natalizumab—has been associated with the development of PML. Although PML in patients treated with natalizumab is a relatively rare event, the risk increases with duration of use of >2 years, prior use of immunosuppressants, and JCV seropositivity. Currently available data suggest that natalizumab-associated PML is associated with a better survival rate compared with PML in other populations, such as in patients with HIV infection (before the availability of highly active antiretroviral therapy) and in transplant recipients. Nonetheless, the natalizumab-associated PML mortality rate is approximately 24%, and surviving patients are frequently left with disability.

Vedolizumab (Entyvio; Takeda Pharmaceuticals, Deerfield, IL, USA) is licensed to treat adults with moderately to severely active ulcerative colitis or Crohn’s disease who have had an inadequate response with, or were intolerant to a tumor necrosis factor (TNF) antagonist or immunomodulator, or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids. As a humanized monoclonal antibody that antagonizes $\alpha_4\beta_7$ integrin, vedolizumab has some similarity in its mechanism of action to that of natalizumab. Natalizumab

Bhayat, and which employed Huifang Liang at the time this analysis was carried out. Timothy Card is employed by the University of Nottingham, and neither he nor the University has received any payment financial or in kind related to this work.

Address correspondence to: Fatima Bhayat, MBChB, PhD, Takeda Development Centre Europe Ltd, 61 Aldwyche, London WC2B 4AE, UK (fatima.bhayat@takeda.com).
is a humanized IgG4 monoclonal antibody that inhibits the α subunit of the αβ integrin, preventing it from binding to vascular cell adhesion molecule 1 (VCAM-1). This results in decreased immune surveillance within the central nervous system (CNS), thus increasing the risk of PML development. However, vedolizumab does not inhibit binding at VCAM-1, and instead selectively targets the αβ integrin expressed on gut-homing lymphocytes, with non-gut-homing T lymphocytes remaining unaffected.

At the time this paper was submitted for publication, there have been no cases of PML reported in association with vedolizumab use. This, combined with the gastrointestinal selective mechanism of action of vedolizumab, supports the hypothesis that this agent does not predispose to the development of PML. However, given the rarity of the condition, the knowledge that the PML risk increases with duration of natalizumab use of >2 years, and the fact that vedolizumab is a relatively novel therapy (US and European approval were obtained in 2014), we cannot yet have absolute confidence in this supposition. Monitoring for new or worsening neurologic signs or symptoms is therefore recommended with vedolizumab treatment, and continued monitoring has been ongoing since clinical development.

Greater certainty regarding the risk of PML with vedolizumab treatment would be of great benefit to patients and clinicians. Hence, our aim here is to use the totality of the available randomized controlled trial (RCT) and observational data to explore how confident we can be that vedolizumab does not predispose to the development of PML.

**METHODS**

**Patients and Data Collection**

The estimated vedolizumab cumulative exposure to May 19, 2016, was calculated based on data from both the clinical trial program (Table; Supplemental Digital Content 1, which lists the clinical studies included in the risk modeling analyses) and postmarketing sales (a total of >8 years in the clinical trial program and up to 2 years’ postmarketing exposure). For clinical trial data, exposure was calculated as the sum of individual exposure periods for each clinical trial patient. For postmarketing data, it was assumed that each patient was treated with vedolizumab 300 mg (1 vial) every 8 weeks. Exposure was calculated based on sales, and to estimate duration of use, we assumed a steady attrition rate between 10% and 30% per year (based on 7-year long-term observational study data) up to the data cutoff point.

Data on adverse events (AEs) up to May 19, 2016, were obtained from the Takeda Global Safety Database, which contains vedolizumab data from clinical trials and postmarketing reporting, held in accordance with routine pharmacovigilance practices. Vedolizumab AE data were obtained from spontaneous reports submitted to Takeda directly from consumers, manufacturers, healthcare professionals, and regulatory authorities; from Takeda monitoring of the scientific and medical literature; and from solicited reports from clinical trials and patient support and market research programs.

From these data (patient-years [PY] of exposure and number of cases of PML), we estimated the risk of PML as cases per 100,000 PY of exposure; 95% confidence intervals (CIs) around this were calculated assuming a Poisson distribution (the probability of observing at least k events was also based on the assumption that events follow a Poisson distribution). The risk estimates were adjusted to account for the increased risk of PML after 2 years of therapy.

**Ethical Considerations**

Patients enrolled in clinical trials, postauthorization safety studies, patient support, and market research programs provided informed consent for participation in the studies, including the collection of AE data. Institutional Review Board review and approvals were obtained for these studies.

**Expected Number of Vedolizumab-Associated PML Cases Relative to Natalizumab**

The total number of expected cases of vedolizumab-associated PML was estimated assuming that vedolizumab use conferred a risk equivalent to that associated with natalizumab use. Previously published rates of PML in natalizumab users were utilized, as described in the US prescribing information and published data (0.56/1000 to 13/1000 over 6 years’ exposure).

Patients were grouped according to level of exposure to vedolizumab and risk factors (prior immunosuppressant use [same risk assumed for all immunosuppressants including azathioprine, methotrexate, and TNF antagonists] and anti-JCV antibody-positive status) to mirror patient stratification described in the natalizumab US prescribing information. To do this, we estimated the levels of prior immunosuppressant use and anti-JCV antibody-positive status. Based on vedolizumab clinical trial data, it was assumed that approximately 80% of patients had prior immunosuppressant use. Because JCV antibody testing was not required by the vedolizumab clinical trial protocols, an estimate was made based on published rates (anti-JCV antibody-positivity was assumed in approximately 50% of patients). Vedolizumab patient counts in each stratum were multiplied by the corresponding risk estimate for natalizumab and summed to obtain the total number of expected cases; the 95% CI estimate (calculated using StatXact 9 software) was based on the normal approximation to the Poisson distribution.

**Expected Number of Vedolizumab-Associated PML Cases Relative to Other Populations**

The expected occurrence of PML in patients receiving vedolizumab was also calculated, assuming the same PML risk factors.
incidence rate (per 100,000 PY) as in the general population and in populations in which the risk of PML is known to be elevated. These groups include patients with rheumatoid arthritis (RA), HIV-free systemic lupus erythematosus (SLE) patients, HIV-free non-Hodgkin’s lymphoma (NHL) patients, HIV-free autoimmune vasculitis patients, HIV-free chronic lymphocytic leukemia patients, bone marrow transplant recipients, patients with HIV, heart and/or lung transplant recipients, and HIV-free rituximab-exposed NHL patients.9, 26–30 The expected number of PML cases and associated 95% CIs for vedolizumab, if the risk were equivalent to each reference population, were calculated by multiplying the population incidence rate (per 100,000 PY) and 95% CI by the total PY of exposure to vedolizumab. Because data for these populations were not reported in strata of immunosuppression use or JCV positivity, it was not possible to standardize these estimates.

Estimated Probability of Future Vedolizumab-Associated PML Cases

The probability of a future PML case in vedolizumab-treated patients was estimated, assuming the same risk as in 3 reference populations: the general population, patients with RA, and patients with SLE (without HIV).26, 27 The current total number of PY of vedolizumab exposure was estimated as specified above (in the Patients and Data Collection section), and the likely future exposure to vedolizumab from 2016 to 2034 was estimated based on sales projections. The probabilities of a case arising for each year were estimated using the Poisson approximation to the binomial distribution (frequentist approach), using the expected cumulative PY by that year as the number of trials and the PML probability in the reference population as the event probability. The probabilities of ≥2 and ≥3 future PML cases in vedolizumab-treated patients were similarly estimated. A sensitivity analysis using a Bayesian approach was also conducted for the general population-based analysis. A conjugate beta distribution was assumed for the prior distribution of the PML probability, with the following 2 shape parameters: α = 1 + number of PML events in current trials (ie, 0), and β = the current total PY + the reciprocal of the estimated PML probability of the general population.31 The predictive probability of ≥1 PML future occurrence for each year was estimated by a beta-binomial distribution based on number of trials equal to the forecasted cumulative PY by that year.

RESULTS

Up to May 19, 2016, the cumulative vedolizumab exposure was approximately 54,619 PY, which comprised 7641 PY (3821 patients) from clinical trials and an estimated 46,978 PY from postmarketing use (Table 1). To date, no cases of PML have been observed in patients treated with vedolizumab. The CI calculated around the rate of 0 cases of PML per 100,000 PY of exposure was 0–6.75 cases of PML per 100,000 PY of exposure.

Expected Number of Vedolizumab-Associated PML Cases

Based on cumulative exposure to vedolizumab, 30.2 cases of PML (95% CI, 19.4–40.9) would be expected if vedolizumab exposure conferred the same risk as that of natalizumab (Table 2). Similarly, given cumulative vedolizumab exposure of approximately 54,619 PY, assuming an equivalent risk to the different reference populations, the number of expected PML cases for vedolizumab-treated patients is lowest in the general population (0.2; 95% CI, 0.05–0.3) and patients with RA (0.6; 95% CI, 0.2–1.4). Higher numbers would be expected in other disease populations, including bone marrow transplant recipients (19.3; 95% CI, 0.5–107.8) and heart and/or lung transplant recipients (67.7; 95% CI, 13.7–197.2), with the highest number anticipated in HIV-free rituximab-exposed NHL patients (131.1; 95% CI, 54.6–305.9) (Table 3).

Estimated Probability of Future Vedolizumab-Associated PML Cases

If the risk of developing PML with vedolizumab were the same as in the general population, the estimated probability of observing the first PML case in vedolizumab-treated

TABLE 1: Estimated Exposure to Vedolizumab (up to May 19, 2016; Data Cutoff)

| Vedolizumab Exposure, mo | Postmarketing: ~46,978 PY* | Clinical Trials: ~7641 PY* | Total: ~54,619 PY |
|-------------------------|----------------------------|---------------------------|------------------|
| 1–24                    | 46,978                     | 2442                      | 49,420           |
| 25–48                   | 0                          | 517                       | 517              |
| 49–72                   | 0                          | 862                       | 862              |
| Total patients          | 46,978                     | 3821                      | 50,799           |

*The number of PY of exposure to vedolizumab in the postmarketing setting is an approximation based on shipping data; it is assumed that each patient received vedolizumab 300 mg (1 vial) every 8 weeks.
patients would be approximately 50% by 2018 and 90% by 2022 (Fig. 1A). An estimated ≥2 or ≥3 cases will occur by 2021 (Fig. 1B) and 2023 (Fig. 1C), respectively, with a >50% probability.

Assuming the risk of PML with vedolizumab were identical to that in patients with RA or HIV-free SLE, the first PML case would be likely to occur earlier than predicted for the general population (≥90% probability of first case by 2019 and 2017, respectively) (Fig. 1A). Assuming the risk is the same as in RA, ≥2 or ≥3 cases would occur with a >90% probability by 2020 and 2021, respectively, and ≥2 or ≥3 cases would occur with a >90% probability by 2018 and 2019, respectively, assuming an identical risk to that in patients with HIV-free SLE (Fig. 1B and C).

In the sensitivity analysis, using the Bayesian approach and historical data of the general population as prior information, we estimate that the probability of observing the first PML case in vedolizumab users will occur with 50% probability during 2019, over a year later than in the estimate based on the frequentist approach (Supplemental Digital Content 2).

DISCUSSION

In this analysis, we provide evidence supporting the hypothesized lower risk of PML in users of vedolizumab versus those of natalizumab. We also estimate the numbers of PML cases that might be expected if vedolizumab users had risk levels equivalent to those of a variety of other population groups. Of the risk of PML in the general population or in patients with RA, HIV-free SLE, HIV-free NHL, or autoimmune vasculitis would be consistent with the observed absence of PML cases to date. The current data are, however, not consistent with vedolizumab carrying the elevated risk of PML seen in HIV infection, heart/lung transplantation, or rituximab use. Because there have been no cases of PML observed to date, it is difficult to precisely estimate the true level of risk, although our current analysis suggests that it is not likely to be above 6.75 cases per 100,000 PY. Assuming an identical risk to that in the general population, the first PML case with vedolizumab treatment was estimated to occur with a 50% probability in 2019 and 2018, using Bayesian and frequentist approaches, respectively.

The analysis we present here has methodological challenges. Because we do not have access to the health records of the vast majority of patients receiving vedolizumab, we have not reviewed individual patients’ medical records to confirm an absence of PML. However, we have gone to great lengths to attempt to ascertain cases through analysis of available RCT and observational data. Bearing in mind the serious nature of PML, it would be expected that all cases occurring in patients receiving vedolizumab in routine clinical practice would be reported. Additionally, direct information regarding prior immunosuppressant use or the presence of JCV in those receiving vedolizumab outside clinical trials is not available. However, there is no reason to believe that those receiving vedolizumab in the postmarketing setting would be less likely to have used immunosuppressants than those in the RCTs. Rather we think it unlikely that many prescribers will yet be using a “top-down” approach starting initial therapy with vedolizumab, or be using it as rescue therapy in acute flares. Immunosuppressant use might well therefore be almost universal in vedolizumab users, in which case the assumption we have made will be highly conservative (we will have underestimated the likely level of PML if risks were equivalent to those in natalizumab).

A further set of challenges with this analysis relates to the available data on population levels of PML. Ideally, we would standardize for age, sex, and immunosuppressant use for all populations; however, the rarity of the condition means that the population data required to achieve this are unavailable. Our estimates, with the exception of that relating to natalizumab, therefore do not take into account any of these confounding factors.

When considering the limitations of this analysis, however, it is important to consider the alternatives. It could be argued that absolute proof that there is no risk could be demonstrated only through a randomized, placebo-controlled clinical trial, with PML development as the primary outcome.
measure and with sufficient power to demonstrate equivalence between vedolizumab-treated patients and those receiving placebo. Such a trial would arguably be unethical and would require an unfeasibly large patient population (for example, in the context of 0 events and based on the statistical “rule of 3”, a sample size of 300,000 PY [for each of the vedolizumab and placebo cohorts] would be required to rule out a risk of >1 event per 100,000 PY with 95% confidence). Therefore, targeted observational research such as the current analysis is likely to be the best available option in this scenario. Due to uncertainty in the current estimate of the true risk of PML associated with vedolizumab, we have provided estimates of the probability of observing future PML cases under various risk scenarios.

Despite the limitations of the available data, it is nonetheless useful to consider the conclusions that can confidently be made. To begin with, it is clear that if the risk of PML were the same as with natalizumab, 30 cases of PML would have been observed by May 19, 2016, in patients treated with vedolizumab, with a 95% CI lower bound of 19 cases. Therefore, we can reasonably conclude that there is a much lower risk of PML with vedolizumab than with natalizumab. Such a conclusion is not surprising because natalizumab is a humanized IgG4 monoclonal antibody that inhibits the α4β1 integrin, preventing it from binding to VCAM-1. By preventing α4β1 binding to VCAM-1 on endothelial cells, extravasation of immune inflammatory cells into the brain is prevented.4, 14 By contrast, vedolizumab is the first available agent that selectively targets the α4β7 integrin heterodimer, specifically preventing extravasation of immune inflammatory cells into the gut, with no evidence of an impact on immune surveillance in the CNS.15–17 We can also conclude that, if the

### TABLE 3: Expected Cases of PML With Vedolizumab Given Current Cumulative Exposure if the Risk Were Equivalent to That of Selected Reference Populations

| Reference Population (Country) | Population Incidence Rate for PML, per 100,000 PY (95% CI) | Expected PML Cases (95% CI)a |
|--------------------------------|-------------------------------------------------------------|-----------------------------|
| General population (Sweden)27  | 0.3 (0.1–0.6)                                               | 0.2 (0.05–0.3)              |
| RA (Sweden)27                  | 1.0 (0.3–2.5)                                               | 0.6 (0.2–1.4)               |
| HIV-free SLE (USA)26           | 2.4 (0.1–13.2)                                              | 1.3 (0.05–7.2)              |
| HIV-free NHL (USA)26           | 8.3 (1.7–24.2)                                              | 4.5 (0.9–13.2)              |
| HIV-free autoimmune vasculitis (USA)26 | 10.8 (0.3–60.4)                               | 5.9 (0.2–33.0)              |
| HIV-free chronic lymphocytic leukemia (USA)26 | 11.1 (0.3–61.7)                           | 6.1 (0.2–33.7)              |
| Bone marrow transplant recipients (USA)26 | 35.4 (0.9–197.3)                        | 19.3 (0.5–107.8)            |
| Patients with HIV (Switzerland)26,b | 60 (40–100)                                               | 32.8 (21.9–54.6)            |
| Heart and/or lung transplant recipients (USA, the Netherlands)9 | 124 (25–361) | 67.7 (13.7–197.2) |
| Patients with HIV (Denmark)28,c | 130 (80–190)                                               | 71.0 (43.7–103.8)           |
| HIV-free rituximab-exposed NHL (Italy)30 | 240 (100–560)                              | 131.1 (54.6–305.9)          |

*Based on cumulative exposure of approximately 54,619 PY using May 19, 2016, estimates from clinical trials (7641 PY) and postmarketing data (46,978 PY).

*Study performed before and after the introduction of combination antiretroviral therapy in 1996.

*Incidence rate covers the period between 2000 and 2006 (late highly active antiretroviral therapy era).

![FIGURE 1. Estimated probability of observing (A) ≥1 PML case, (B) ≥2 PML cases, and (C) ≥3 PML cases with vedolizumab over time, assuming equivalent risk to reference populations.](https://academic.oup.com/ibdjournal/article-abstract/24/5/953/4969878)
PML risk does not increase with long-term vedolizumab use, it is unlikely that the true level of risk is above 6.75 cases per 100,000 PY given current exposure estimates.

To put this into context, such a risk should be compared not only with the known risk of PML associated with other treatments (as has been done here), but also with the uncertainty regarding other medications such as corticosteroids and thioguanines, which have both been associated with the development of this condition. A 2009 study of nationwide US patient sample data showed that 20% of cases of PML in rheumatic diseases were associated with the use of only very mild immunosuppression with an antimalarial or low-dose prednisolone, and analysis of French pharmacovigilance reports shows that PML has significantly elevated reported odds ratios (in excess of 4) for both prednisolone and azathioprine. Finally, we should consider what other risks patients might run with alternative therapies. In many cases, the alternatives to vedolizumab will be either immunosuppression or surgery. Neither of these is risk-free, with a colectomy being associated with mortality of about 1% and azathioprine with a cumulative lymphoma risk of approximately 0.4–4.0% over 10 years (depending on age).

In conclusion, our calculations have shown that the risk of PML with vedolizumab is likely to be significantly lower than that with natalizumab. With no cases having been reported to date, the eventual level of risk cannot be precisely estimated; however, these analyses indicate that the risk is small, and unlikely to be above 6.75 cases per 100,000 PY. Confirmation as to whether the risk is appreciably greater than in the background population remains to be seen as further data are accrued from continued postmarketing surveillance.

SUPPLEMENTARY DATA

Supplementary data are available at Inflammatory Bowel Diseases online.

ACKNOWLEDGMENTS

The authors would like to thank the following: Wei Zhong of Takeda Development Center Americas, Inc., for his assistance with the Bayesian model; Jesse Shick, formerly of Takeda Development Center Americas, USA, for his contribution to the development of this manuscript, including his participation in concept/study discussions, analysis of data, and review of initial drafts; and William Palo, formerly of Takeda Development Center Americas, USA, for his contribution to the development of this manuscript, including providing statistical support, analysis of data, participating in concept/study discussions, and review of initial drafts. This study was supported by Takeda Pharmaceutical Company Ltd. Medical writing support was provided by Khalid Siddiqui of Chameleon Communications International Ltd, UK (a Healthcare Consultancy Group Company), and sponsored by Takeda Pharmaceutical Company Ltd.

Author contributions: Timothy Card contributed to the study design, data interpretation, writing of the first and all subsequent drafts of the manuscript, and final approval of the manuscript. Jing Xu contributed to the study design, statistical analyses and modeling, data interpretation, writing of the first and all subsequent drafts of the manuscript, and final approval of the manuscript. Huifang Liang contributed to the study design, the literature review of PML incidence rates in different populations, data interpretation, manuscript writing, critical revision for important intellectual content, and final approval of the manuscript. Fatima Bhayat contributed to the study design, data interpretation, writing of the first and all subsequent drafts of the manuscript, and final approval of the manuscript.

REFERENCES

1. Adang L, Berger J. Progressive multifocal leukoencephalopathy. F1000Res. 2015;4 pii.
2. Tan CS, Korahink IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010;9:425–437.
3. Hunt D, Giovannoni G. Natalizumab-associated progressive multifocal leukoencephalopathy: a practical approach to risk profiling and monitoring. Pract Neurol. 2012;12:25–35.
4. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med. 2010;61:35–47.
5. Bloomgren G, Richman S, Hotermans C et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870–1880.
6. Berger J, Fox RJ. Reassessing the risk of natalizumab-associated PML. J Neurol 2016;22:533–535.
7. Berger JR, Pall L, Lanska D, Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurol. 1998;4:59–68.
8. Dong-Si T, Gheuens S, Gangadharan A, et al. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy. J Neurol. 2015;213:637–644.
9. Mateen FJ, Muralidharan R, Carone M, et al. Progressive multifocal leukoencephalopathy in transplant recipients. Ann Neurol. 2011;70:305–322.
10. Vermeersch P, Kappos L, Gold R, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology. 2011;76:1697–1704.
11. Takeda Pharmaceuticals America Inc. ENTYVIO® (vedolizumab) Prescribing Information. 2014. Available at: http://general.takedapharm.com/content/file.aspx?filetypecode=ENTYVIOPL&CountryCode=US&LanguageCode=EN&cacheRandomizer=88f671bd-13ec-455d-88b1-04d384774279a. Accessed August 22, 2017.
12. Biogen Idec Inc, Tysabri (Natalizumab) Summary of Product Characteristics. 2016. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000603/human_med_001119.jsp&mid=W-C0601ae0588013d124. Accessed February 17, 2017.
13. Takeda Pharma A/S. ENTYVIO® (vedolizumab) Summary of Product Characteristics. 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000278/WC50018528.pdf. Accessed August 2017.
14. McLean LP, Shea-Donohue T, Cross RK. Vedolizumab for the treatment of ulcerative colitis and Crohn’s disease. Immunotherapy. 2012;4:883–898.
15. Soler D, Chapman T, Yang LL et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha beta integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330:864–875.
16. Fedyk ER, Wiant Y, Yang LL et al. Exclusive antagonism of the a4 beta7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis. 2012;18:2107–2119.
17. Milch C, Wiant T, Xu J, et al. Vedolizumab, a monoclonal antibody to the gut homing alpha4beta7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype. J Neuroimmunol. 2013;264:123–126.
18. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.
Is Vedolizumab Treatment a Risk for PML?

19. Sandborn WJ, Feagan BG, Rutgeert P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. *N Engl J Med*. 2013;369:711–721.

20. Sands BE, Feagan BG, Rutgeert P, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. *Gastroenterology*. 2014;147:618–627.e3.

21. Biogen Idec Inc. Tysabri (Natalizumab) Prescribing information. 2015. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125104s950lbl.pdf. Accessed January 23, 2017.

22. Colombel JF, Sands BE, Rutgeert P, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. *Gut*. 2017;66:839–851.

23. Wollebo HS, White MK, Gordon J, et al. Persistence and pathogenesis of the neurotropic polyomavirus JC. *Ann Neurol*. 2015;77:560–570.

24. Pepio AM, Taylor L, Jaros M, et al. Evaluation of the incidence of anti-JC virus antibodies in a cohort of natalizumab-treated patients. *Gastroenterology*. 2011;140:857-868.

25. Cytel Software Corporation. StatXact 9. 2010. Available at: http://www.cytel.com/hubfs/0-library-0/pdfs/SX9_brochure_final-2.pdf. Accessed January 23, 2017.

26. Amend KL, Turnbull B, Foskett N, et al. Incidence of progressive multifocal leukoencephalopathy in patients without HIV. *Neurology*. 2010;75:1326–1332.

27. Arkema EV, van Vollenhoven RF, Askling J. Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study. *Ann Rheum Dis*. 2012;71:1865–1867.

28. Engsig FN, Hansen AB, Omland LH, et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. *J Infect Dis*. 2009;199:77–83.

29. Khanna N, Elzi L, Mueller NJ, et al. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. *Clin Infect Dis*. 2009;48:1459–1466.

30. Tucori M, Focosi D, Blandizzi C, et al. Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy. *Oncologist*. 2010;15:1214–1219.

31. Jovanovic BD, Levy PS. A look at the rule of three. *Am Stat*. 1997;51:137–139.

32. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. *Arthritis Rheum*. 2009;60:3761–3765.

33. Colin O, Favoriere S, Quillet A, et al. Drug-induced progressive multifocal leukoencephalopathy: a case/noncase study in the French pharmacovigilance database. *Fundam Clin Pharmacol*. 2017;31:237–244.

34. Tøttrup A, Eriksen R, Sværke C, et al. Thirty-day mortality after elective and emergency total colectomy in Danish patients with inflammatory bowel disease: a population-based nationwide cohort study. *BMJ Open*. 2012;2:e000823.

35. Louis E, Irving P, Beaugerie L. Use of azathioprine in IBD: modern aspects of an old drug. *Gut*. 2014;63:1695–1699.